Utils function for FAERSascii class.
faers_get(object, ...)
# S4 method for class 'FAERSascii'
faers_get(object, field)
faers_mget(object, ...)
# S4 method for class 'FAERSascii'
faers_mget(object, fields)
faers_primaryid(object, ...)
# S4 method for class 'FAERSascii'
faers_primaryid(object)
# S4 method for class 'FAERSascii,ANY,ANY,ANY'
x[i]
# S4 method for class 'FAERSascii'
x[[i]]
# S4 method for class 'FAERSascii'
x$name
faers_keep(object, ...)
# S4 method for class 'FAERSascii'
faers_keep(object, primaryid = NULL, invert = FALSE)
faers_filter(.object, ...)
# S4 method for class 'FAERSascii'
faers_filter(.object, .fn, ..., .field = NULL, .invert = FALSE)
faers_modify(.object, ...)
# S4 method for class 'FAERSascii'
faers_modify(.object, .field, .fn, ...)A FAERSascii object.
Other arguments passed to specific methods. For faers_filter:
other arguments passed to .fn.
A string indicates the FAERS fields to use. Only values "demo", "drug", "indi", "reac", "ther", "rpsr", and "outc" can be used.
A character vector specifying the fields to use. Only values "demo", "drug", "indi", "ther", "reac", "rpsr", and "outc" can be used.
A FAERSascii object.
Indices specifying elements to extract. For i, it will be
okay to use integer indices.
An atomic character or integer specifies the reports to
keep. If NULL, will do nothing.
A bool. If TRUE, will keep reports not in primaryid.
A function or formula, accept the field data as the input and
return an atomic integer or character of primaryid you want to keep or
remove based on argument .invert.
If a function, it is used as is.
If a formula, e.g. ~ .x + 2, it is converted to a function with up to
two arguments: .x (single argument) or .x and .y (two arguments). The
. placeholder can be used instead of .x. This allows you to create
very compact anonymous functions (lambdas) with up to two inputs.
If a string, the function is looked up in globalenv().
A string indicating the FAERS data to be used as input for the
.fn function to extract the primaryid or modify data. Only the following
values can be used: "demo", "drug", "indi", "ther", "reac", "rpsr", and
"outc".
faers_filter: Use .fn to extract primaryid. If NULL, .object will
be passed directly to .fn. .fn should return an atomic integer or
character of primaryid that you want to keep or remove based on the
.invert argument.
faers_modify: Use .fn to modify the specified field data. You cannot
use NULL here. .fn should always return a
data.table.
A bool. If TRUE, will keep reports not returned by .fn.
See details.
faers_get: Extract a specific field
data.table. For reac and indi field, meddra
data will be automatically added if avaliable.
faers_mget: Extract a list of field
data.table. For reac and indi field, meddra
data will be automatically added if avaliable.
[[, $, and [: Extract a specific field
data.table or a list of field
data.table from FAERS object. Note: this just
extract field data from @data slot directly. For usual usage, just use
faers_get or faers_mget.
faers_primaryid: Extract the primaryid from demo field.
faers_keep: only keep data from specified primaryid. Note: year,
quarter, deletedCases will be kept as the original. So make sure you
didn't filter a whole period FAERS quarterly data, in this way, it's much
better to run faers.
faers_filter: apply a function to extract the wanted primaryid, then
use faers_keep to keep data from these primaryids.
# you must change `dir`, as the file included in the package is sampled
data <- faers(2004, "q1",
dir = system.file("extdata", package = "faers"),
compress_dir = tempdir()
)
#> Finding 1 file already downloaded: aers_ascii_2004q1.zip
faers_get(data, "indi")
#> year quarter primaryid indi_drug_seq
#> <int> <char> <char> <int>
#> 1: 2004 q1 4263927 1004493661
#> 2: 2004 q1 4264001 1004493811
#> 3: 2004 q1 4264001 1004520441
#> 4: 2004 q1 4264001 1004520538
#> 5: 2004 q1 4264319 1004494389
#> ---
#> 153: 2004 q1 4338901 1004786888
#> 154: 2004 q1 4346899 1004815291
#> 155: 2004 q1 4346899 1004815291
#> 156: 2004 q1 4347265 1004816501
#> 157: 2004 q1 4373559 1004923573
#> indi_pt
#> <char>
#> 1: DIABETES MELLITUS NON-INSULIN-DEPENDENT
#> 2: RHEUMATOID ARTHRITIS
#> 3: RHEUMATOID ARTHRITIS
#> 4: RHEUMATOID ARTHRITIS
#> 5: ANTIVIRAL PROPHYLAXIS
#> ---
#> 153: RHEUMATOID ARTHRITIS
#> 154: ATTENTION DEFICIT/HYPERACTIVITY DISORDER
#> 155: PERVASIVE DEVELOPMENTAL DISORDER
#> 156: FRACTURED SACRUM
#> 157: LIPIDS INCREASED
data[["indi"]]
#> year quarter primaryid indi_drug_seq
#> <int> <char> <char> <int>
#> 1: 2004 q1 4263927 1004493661
#> 2: 2004 q1 4264001 1004493811
#> 3: 2004 q1 4264001 1004520441
#> 4: 2004 q1 4264001 1004520538
#> 5: 2004 q1 4264319 1004494389
#> ---
#> 153: 2004 q1 4338901 1004786888
#> 154: 2004 q1 4346899 1004815291
#> 155: 2004 q1 4346899 1004815291
#> 156: 2004 q1 4347265 1004816501
#> 157: 2004 q1 4373559 1004923573
#> indi_pt
#> <char>
#> 1: DIABETES MELLITUS NON-INSULIN-DEPENDENT
#> 2: RHEUMATOID ARTHRITIS
#> 3: RHEUMATOID ARTHRITIS
#> 4: RHEUMATOID ARTHRITIS
#> 5: ANTIVIRAL PROPHYLAXIS
#> ---
#> 153: RHEUMATOID ARTHRITIS
#> 154: ATTENTION DEFICIT/HYPERACTIVITY DISORDER
#> 155: PERVASIVE DEVELOPMENTAL DISORDER
#> 156: FRACTURED SACRUM
#> 157: LIPIDS INCREASED
data$indi
#> year quarter primaryid indi_drug_seq
#> <int> <char> <char> <int>
#> 1: 2004 q1 4263927 1004493661
#> 2: 2004 q1 4264001 1004493811
#> 3: 2004 q1 4264001 1004520441
#> 4: 2004 q1 4264001 1004520538
#> 5: 2004 q1 4264319 1004494389
#> ---
#> 153: 2004 q1 4338901 1004786888
#> 154: 2004 q1 4346899 1004815291
#> 155: 2004 q1 4346899 1004815291
#> 156: 2004 q1 4347265 1004816501
#> 157: 2004 q1 4373559 1004923573
#> indi_pt
#> <char>
#> 1: DIABETES MELLITUS NON-INSULIN-DEPENDENT
#> 2: RHEUMATOID ARTHRITIS
#> 3: RHEUMATOID ARTHRITIS
#> 4: RHEUMATOID ARTHRITIS
#> 5: ANTIVIRAL PROPHYLAXIS
#> ---
#> 153: RHEUMATOID ARTHRITIS
#> 154: ATTENTION DEFICIT/HYPERACTIVITY DISORDER
#> 155: PERVASIVE DEVELOPMENTAL DISORDER
#> 156: FRACTURED SACRUM
#> 157: LIPIDS INCREASED
faers_get(data, "demo")
#> year quarter primaryid caseid i_f_code foll_seq image event_dt
#> <int> <char> <char> <char> <char> <int> <char> <int>
#> 1: 2004 q1 4263764 4060920 I NA 4263764-6 20020101
#> 2: 2004 q1 4263927 4064250 I NA 4263927-X NA
#> 3: 2004 q1 4264001 4062524 I NA 4264001-9 20031218
#> 4: 2004 q1 4264319 4064506 I NA 4264319-X 20031216
#> 5: 2004 q1 4266745 4056689 I NA 4266745-1 20030529
#> 6: 2004 q1 4268568 4059382 I NA 4268568-6 NA
#> 7: 2004 q1 4268586 3994383 F NA 4268586-8 20030826
#> 8: 2004 q1 4269553 4061181 I NA 4269553-0 20040105
#> 9: 2004 q1 4269590 4062932 I NA 4269590-6 20030602
#> 10: 2004 q1 4269894 4068631 I NA 4269894-7 20030805
#> 11: 2004 q1 4270064 4062312 I NA 4270064-7 NA
#> 12: 2004 q1 4271501 4007339 F 1 4271501-4 20020729
#> 13: 2004 q1 4272687 4072288 I NA 4272687-8 20031220
#> 14: 2004 q1 4274829 4073121 I NA 4274829-7 NA
#> 15: 2004 q1 4276604 4019165 F 2 4276604-6 NA
#> 16: 2004 q1 4276994 4062516 F 2 4276994-4 20031101
#> 17: 2004 q1 4277521 4027660 F 1 4277521-8 NA
#> 18: 2004 q1 4279336 4022360 F 1 4279336-3 20030911
#> 19: 2004 q1 4280316 4049927 F 1 4280316-2 20030617
#> 20: 2004 q1 4280654 4081346 I NA 4280654-3 20040112
#> 21: 2004 q1 4281199 4093363 I NA 4281199-7 NA
#> 22: 2004 q1 4281267 4074460 I NA 4281267-X 20031111
#> 23: 2004 q1 4283791 4091687 I NA 4283791-2 NA
#> 24: 2004 q1 4283960 4008465 F NA 4283960-1 20010717
#> 25: 2004 q1 4284513 4084187 I NA 4284513-1 20030101
#> 26: 2004 q1 4284876 4086360 I NA 4284876-7 NA
#> 27: 2004 q1 4285379 4078728 F 1 4285379-6 20030813
#> 28: 2004 q1 4286029 4087281 I NA 4286029-5 NA
#> 29: 2004 q1 4286712 4072824 F 1 4286712-1 20031209
#> 30: 2004 q1 4286757 4081521 F NA 4286757-1 20031214
#> 31: 2004 q1 4286940 4088359 I NA 4286940-5 20030121
#> 32: 2004 q1 4287019 4088362 I NA 4287019-9 20040121
#> 33: 2004 q1 4289563 4091829 I NA 4289563-7 20030901
#> mfr_dt fda_dt rept_cod mfr_num
#> <int> <int> <char> <char>
#> 1: 20031219 20040102 EXP USA031255171
#> 2: 20031209 20040102 EXP B0317710A
#> 3: 20031219 20040102 EXP JP-JNJFOC-20031204393
#> 4: 20031218 20040105 EXP MEDI-0001221
#> 5: 20040105 20040108 EXP FR-GLAXOSMITHKLINE-B0318977A
#> 6: 20040107 20040112 EXP PHBS2004JP00548
#> 7: 20030904 20040112 EXP US-GLAXOSMITHKLINE-A0424697A
#> 8: 20040106 20040113 EXP US-BRISTOL-MYERS SQUIBB COMPANY-12471421
#> 9: NA 20040112 DIR <NA>
#> 10: NA 20040112 DIR <NA>
#> 11: 20030204 20040114 PER US-GLAXOSMITHKLINE-A0395406A
#> 12: 20040106 20040113 EXP TPA2003A01222
#> 13: 20040109 20040115 EXP 04-01-0044
#> 14: 20031231 20040115 EXP USA040155657
#> 15: 20040108 20040120 EXP US-SHR-03-015202
#> 16: 20040105 20040120 EXP 03P-062-0245595-00
#> 17: 20040105 20040121 EXP DSA_23477_2003
#> 18: 20040112 20040122 EXP FR-JNJFOC-20030905591
#> 19: 20040115 20040126 EXP UK059122
#> 20: 20040119 20040123 EXP 200410213GDS
#> 21: 20030911 20040108 PER HQWYE745017SEP03
#> 22: 20031201 20040123 PER DL2003219
#> 23: 20030415 20040115 PER NSADSS2003017923
#> 24: 20031002 20040202 EXP WAES 0310USA00338
#> 25: NA 20040130 DIR <NA>
#> 26: 20040119 20040202 EXP A001-002-005955
#> 27: 20040121 20040202 EXP 2004194398JP
#> 28: 20040122 20040203 EXP 2004004976
#> 29: 20040126 20040204 EXP 2004193432JP
#> 30: 20040127 20040206 EXP IT-GLAXOSMITHKLINE-B0321668A
#> 31: 20040129 20040205 EXP USA-2004-0012715
#> 32: 20040121 20040205 EXP US_0401100140
#> 33: 20031020 20040126 PER USA030948470
#> mfr_sndr age age_cod gender e_sub wt
#> <char> <num> <char> <char> <char> <num>
#> 1: ELI LILLY AND COMPANY 68 YR F N 82.0
#> 2: GLAXOSMITHKLINE GLOBAL CLINICAL SAFETY 58 YR F N NA
#> 3: CENTOCOR, INC. 53 YR F N 36.8
#> 4: MEDIMUNE, INC. NA <NA> F N NA
#> 5: GLAXOSMITHKLINE 48 YR F Y NA
#> 6: NOVARTIS PHARMACEUTICALS CORP. NA <NA> M Y NA
#> 7: GLAXOSMITHKLINE 13 YR F Y NA
#> 8: BRISTOL-MYERS SQUIBB COMPANY 10 DEC F Y NA
#> 9: <NA> 57 YR M N NA
#> 10: <NA> 90 YR M N NA
#> 11: GLAXOSMITHKLINE NA <NA> <NA> Y NA
#> 12: TAKEDA PHARMACEUTICALS NORTH AMERICA. 71 YR M N 160.0
#> 13: IVAX PHARMACEUTICALS, INC. 71 YR F N NA
#> 14: ELI LILLY AND COMPANY 79 YR F N NA
#> 15: BERLEX LABORATORIES NA <NA> F N 79.4
#> 16: PPD PHARMACOVIGILANCE NA <NA> F N NA
#> 17: BIOVAIL PHARMACEUTICALS INC. 61 YR M N 204.0
#> 18: CENTOCOR, INC. 31 YR F N NA
#> 19: AMGEN 65 YR F N 63.0
#> 20: BAYER PHARMACEUTICALS CORPORATION 17 YR F N NA
#> 21: WYETH LABS (RA) NA <NA> F N NA
#> 22: DANCO LABORATORIES, LLC NA <NA> F N NA
#> 23: JOHNSON + JOHNSON PHARMACEUTICAL 85 YR F N NA
#> 24: MERCK HUMAN HEALTH DIVISION 55 YR M Y NA
#> 25: <NA> 73 YR M N NA
#> 26: EISAI INC. NA <NA> F N NA
#> 27: PFIZER INC. 72 YR F N 52.0
#> 28: WWS PFIZER PHARMACEUTICALS NA <NA> M N NA
#> 29: PFIZER INC. 53 YR M N NA
#> 30: GLAXOSMITHKLINE 17 YR F Y NA
#> 31: PURDUE PHARMA L.P. 38 YR F N NA
#> 32: ELI LILLY AND COMPANY NA <NA> F N NA
#> 33: ELI LILLY AND COMPANY 79 YR F N NA
#> wt_cod rept_dt occp_cod death_dt to_mfr confid v23 caseversion
#> <char> <int> <char> <lgcl> <char> <char> <lgcl> <int>
#> 1: KG 20031223 <NA> NA <NA> <NA> NA 0
#> 2: <NA> 20031219 <NA> NA <NA> <NA> NA 0
#> 3: KG 20031231 MD NA <NA> <NA> NA 0
#> 4: <NA> 20031231 MD NA <NA> <NA> NA 0
#> 5: <NA> 20040108 CN NA <NA> <NA> NA 0
#> 6: <NA> 20040109 MD NA <NA> <NA> NA 0
#> 7: <NA> 20040112 CN NA <NA> <NA> NA 0
#> 8: <NA> 20040113 OT NA <NA> <NA> NA 0
#> 9: <NA> NA PH NA N Y NA 0
#> 10: <NA> NA <NA> NA N Y NA 0
#> 11: <NA> 20040114 CN NA <NA> <NA> NA 0
#> 12: LBS 20040112 MD NA <NA> <NA> NA 0
#> 13: <NA> 20040109 OT NA <NA> <NA> NA 0
#> 14: <NA> 20040107 <NA> NA <NA> <NA> NA 0
#> 15: KG 20040116 CN NA <NA> <NA> NA 0
#> 16: <NA> 20040105 MD NA <NA> <NA> NA 0
#> 17: LBS 20040120 MD NA <NA> <NA> NA 0
#> 18: <NA> 20040121 MD NA <NA> <NA> NA 0
#> 19: KG 20040123 <NA> NA <NA> <NA> NA 0
#> 20: <NA> 20040122 MD NA <NA> <NA> NA 0
#> 21: <NA> 20031223 <NA> NA <NA> <NA> NA 0
#> 22: <NA> 20031229 OT NA <NA> <NA> NA 0
#> 23: <NA> 20040108 OT NA <NA> <NA> NA 0
#> 24: <NA> 20040203 MD NA <NA> <NA> NA 0
#> 25: <NA> 20030124 OT NA Y N NA 0
#> 26: <NA> 20040123 MD NA <NA> <NA> NA 0
#> 27: KG 20040130 MD NA <NA> <NA> NA 0
#> 28: <NA> 20040202 CN NA <NA> <NA> NA 0
#> 29: <NA> 20040202 OT NA <NA> <NA> NA 0
#> 30: <NA> 20040206 CN NA <NA> <NA> NA 0
#> 31: <NA> 20040204 OT NA <NA> <NA> NA 0
#> 32: <NA> 20040128 <NA> NA <NA> <NA> NA 0
#> 33: <NA> 20031208 MD NA <NA> <NA> NA 0
#> age_in_years country_code sex
#> <num> <char> <char>
#> 1: 68 <NA> Female
#> 2: 58 <NA> Female
#> 3: 53 <NA> Female
#> 4: NA <NA> Female
#> 5: 48 <NA> Female
#> 6: NA <NA> Male
#> 7: 13 <NA> Female
#> 8: 120 <NA> Female
#> 9: 57 <NA> Male
#> 10: 90 <NA> Male
#> 11: NA <NA> <NA>
#> 12: 71 <NA> Male
#> 13: 71 <NA> Female
#> 14: 79 <NA> Female
#> 15: NA <NA> Female
#> 16: NA <NA> Female
#> 17: 61 <NA> Male
#> 18: 31 <NA> Female
#> 19: 65 <NA> Female
#> 20: 17 <NA> Female
#> 21: NA <NA> Female
#> 22: NA <NA> Female
#> 23: 85 <NA> Female
#> 24: 55 <NA> Male
#> 25: 73 <NA> Male
#> 26: NA <NA> Female
#> 27: 72 <NA> Female
#> 28: NA <NA> Male
#> 29: 53 <NA> Male
#> 30: 17 <NA> Female
#> 31: 38 <NA> Female
#> 32: NA <NA> Female
#> 33: 79 <NA> Female
#> [ reached 'max' / getOption("max.print") -- omitted 68 rows ]
data[["demo"]]
#> year quarter primaryid caseid i_f_code foll_seq image event_dt
#> <int> <char> <char> <char> <char> <int> <char> <int>
#> 1: 2004 q1 4263764 4060920 I NA 4263764-6 20020101
#> 2: 2004 q1 4263927 4064250 I NA 4263927-X NA
#> 3: 2004 q1 4264001 4062524 I NA 4264001-9 20031218
#> 4: 2004 q1 4264319 4064506 I NA 4264319-X 20031216
#> 5: 2004 q1 4266745 4056689 I NA 4266745-1 20030529
#> 6: 2004 q1 4268568 4059382 I NA 4268568-6 NA
#> 7: 2004 q1 4268586 3994383 F NA 4268586-8 20030826
#> 8: 2004 q1 4269553 4061181 I NA 4269553-0 20040105
#> 9: 2004 q1 4269590 4062932 I NA 4269590-6 20030602
#> 10: 2004 q1 4269894 4068631 I NA 4269894-7 20030805
#> 11: 2004 q1 4270064 4062312 I NA 4270064-7 NA
#> 12: 2004 q1 4271501 4007339 F 1 4271501-4 20020729
#> 13: 2004 q1 4272687 4072288 I NA 4272687-8 20031220
#> 14: 2004 q1 4274829 4073121 I NA 4274829-7 NA
#> 15: 2004 q1 4276604 4019165 F 2 4276604-6 NA
#> 16: 2004 q1 4276994 4062516 F 2 4276994-4 20031101
#> 17: 2004 q1 4277521 4027660 F 1 4277521-8 NA
#> 18: 2004 q1 4279336 4022360 F 1 4279336-3 20030911
#> 19: 2004 q1 4280316 4049927 F 1 4280316-2 20030617
#> 20: 2004 q1 4280654 4081346 I NA 4280654-3 20040112
#> 21: 2004 q1 4281199 4093363 I NA 4281199-7 NA
#> 22: 2004 q1 4281267 4074460 I NA 4281267-X 20031111
#> 23: 2004 q1 4283791 4091687 I NA 4283791-2 NA
#> 24: 2004 q1 4283960 4008465 F NA 4283960-1 20010717
#> 25: 2004 q1 4284513 4084187 I NA 4284513-1 20030101
#> 26: 2004 q1 4284876 4086360 I NA 4284876-7 NA
#> 27: 2004 q1 4285379 4078728 F 1 4285379-6 20030813
#> 28: 2004 q1 4286029 4087281 I NA 4286029-5 NA
#> 29: 2004 q1 4286712 4072824 F 1 4286712-1 20031209
#> 30: 2004 q1 4286757 4081521 F NA 4286757-1 20031214
#> 31: 2004 q1 4286940 4088359 I NA 4286940-5 20030121
#> 32: 2004 q1 4287019 4088362 I NA 4287019-9 20040121
#> 33: 2004 q1 4289563 4091829 I NA 4289563-7 20030901
#> mfr_dt fda_dt rept_cod mfr_num
#> <int> <int> <char> <char>
#> 1: 20031219 20040102 EXP USA031255171
#> 2: 20031209 20040102 EXP B0317710A
#> 3: 20031219 20040102 EXP JP-JNJFOC-20031204393
#> 4: 20031218 20040105 EXP MEDI-0001221
#> 5: 20040105 20040108 EXP FR-GLAXOSMITHKLINE-B0318977A
#> 6: 20040107 20040112 EXP PHBS2004JP00548
#> 7: 20030904 20040112 EXP US-GLAXOSMITHKLINE-A0424697A
#> 8: 20040106 20040113 EXP US-BRISTOL-MYERS SQUIBB COMPANY-12471421
#> 9: NA 20040112 DIR <NA>
#> 10: NA 20040112 DIR <NA>
#> 11: 20030204 20040114 PER US-GLAXOSMITHKLINE-A0395406A
#> 12: 20040106 20040113 EXP TPA2003A01222
#> 13: 20040109 20040115 EXP 04-01-0044
#> 14: 20031231 20040115 EXP USA040155657
#> 15: 20040108 20040120 EXP US-SHR-03-015202
#> 16: 20040105 20040120 EXP 03P-062-0245595-00
#> 17: 20040105 20040121 EXP DSA_23477_2003
#> 18: 20040112 20040122 EXP FR-JNJFOC-20030905591
#> 19: 20040115 20040126 EXP UK059122
#> 20: 20040119 20040123 EXP 200410213GDS
#> 21: 20030911 20040108 PER HQWYE745017SEP03
#> 22: 20031201 20040123 PER DL2003219
#> 23: 20030415 20040115 PER NSADSS2003017923
#> 24: 20031002 20040202 EXP WAES 0310USA00338
#> 25: NA 20040130 DIR <NA>
#> 26: 20040119 20040202 EXP A001-002-005955
#> 27: 20040121 20040202 EXP 2004194398JP
#> 28: 20040122 20040203 EXP 2004004976
#> 29: 20040126 20040204 EXP 2004193432JP
#> 30: 20040127 20040206 EXP IT-GLAXOSMITHKLINE-B0321668A
#> 31: 20040129 20040205 EXP USA-2004-0012715
#> 32: 20040121 20040205 EXP US_0401100140
#> 33: 20031020 20040126 PER USA030948470
#> mfr_sndr age age_cod gender e_sub wt
#> <char> <num> <char> <char> <char> <num>
#> 1: ELI LILLY AND COMPANY 68 YR F N 82.0
#> 2: GLAXOSMITHKLINE GLOBAL CLINICAL SAFETY 58 YR F N NA
#> 3: CENTOCOR, INC. 53 YR F N 36.8
#> 4: MEDIMUNE, INC. NA <NA> F N NA
#> 5: GLAXOSMITHKLINE 48 YR F Y NA
#> 6: NOVARTIS PHARMACEUTICALS CORP. NA <NA> M Y NA
#> 7: GLAXOSMITHKLINE 13 YR F Y NA
#> 8: BRISTOL-MYERS SQUIBB COMPANY 10 DEC F Y NA
#> 9: <NA> 57 YR M N NA
#> 10: <NA> 90 YR M N NA
#> 11: GLAXOSMITHKLINE NA <NA> <NA> Y NA
#> 12: TAKEDA PHARMACEUTICALS NORTH AMERICA. 71 YR M N 160.0
#> 13: IVAX PHARMACEUTICALS, INC. 71 YR F N NA
#> 14: ELI LILLY AND COMPANY 79 YR F N NA
#> 15: BERLEX LABORATORIES NA <NA> F N 79.4
#> 16: PPD PHARMACOVIGILANCE NA <NA> F N NA
#> 17: BIOVAIL PHARMACEUTICALS INC. 61 YR M N 204.0
#> 18: CENTOCOR, INC. 31 YR F N NA
#> 19: AMGEN 65 YR F N 63.0
#> 20: BAYER PHARMACEUTICALS CORPORATION 17 YR F N NA
#> 21: WYETH LABS (RA) NA <NA> F N NA
#> 22: DANCO LABORATORIES, LLC NA <NA> F N NA
#> 23: JOHNSON + JOHNSON PHARMACEUTICAL 85 YR F N NA
#> 24: MERCK HUMAN HEALTH DIVISION 55 YR M Y NA
#> 25: <NA> 73 YR M N NA
#> 26: EISAI INC. NA <NA> F N NA
#> 27: PFIZER INC. 72 YR F N 52.0
#> 28: WWS PFIZER PHARMACEUTICALS NA <NA> M N NA
#> 29: PFIZER INC. 53 YR M N NA
#> 30: GLAXOSMITHKLINE 17 YR F Y NA
#> 31: PURDUE PHARMA L.P. 38 YR F N NA
#> 32: ELI LILLY AND COMPANY NA <NA> F N NA
#> 33: ELI LILLY AND COMPANY 79 YR F N NA
#> wt_cod rept_dt occp_cod death_dt to_mfr confid v23 caseversion
#> <char> <int> <char> <lgcl> <char> <char> <lgcl> <int>
#> 1: KG 20031223 <NA> NA <NA> <NA> NA 0
#> 2: <NA> 20031219 <NA> NA <NA> <NA> NA 0
#> 3: KG 20031231 MD NA <NA> <NA> NA 0
#> 4: <NA> 20031231 MD NA <NA> <NA> NA 0
#> 5: <NA> 20040108 CN NA <NA> <NA> NA 0
#> 6: <NA> 20040109 MD NA <NA> <NA> NA 0
#> 7: <NA> 20040112 CN NA <NA> <NA> NA 0
#> 8: <NA> 20040113 OT NA <NA> <NA> NA 0
#> 9: <NA> NA PH NA N Y NA 0
#> 10: <NA> NA <NA> NA N Y NA 0
#> 11: <NA> 20040114 CN NA <NA> <NA> NA 0
#> 12: LBS 20040112 MD NA <NA> <NA> NA 0
#> 13: <NA> 20040109 OT NA <NA> <NA> NA 0
#> 14: <NA> 20040107 <NA> NA <NA> <NA> NA 0
#> 15: KG 20040116 CN NA <NA> <NA> NA 0
#> 16: <NA> 20040105 MD NA <NA> <NA> NA 0
#> 17: LBS 20040120 MD NA <NA> <NA> NA 0
#> 18: <NA> 20040121 MD NA <NA> <NA> NA 0
#> 19: KG 20040123 <NA> NA <NA> <NA> NA 0
#> 20: <NA> 20040122 MD NA <NA> <NA> NA 0
#> 21: <NA> 20031223 <NA> NA <NA> <NA> NA 0
#> 22: <NA> 20031229 OT NA <NA> <NA> NA 0
#> 23: <NA> 20040108 OT NA <NA> <NA> NA 0
#> 24: <NA> 20040203 MD NA <NA> <NA> NA 0
#> 25: <NA> 20030124 OT NA Y N NA 0
#> 26: <NA> 20040123 MD NA <NA> <NA> NA 0
#> 27: KG 20040130 MD NA <NA> <NA> NA 0
#> 28: <NA> 20040202 CN NA <NA> <NA> NA 0
#> 29: <NA> 20040202 OT NA <NA> <NA> NA 0
#> 30: <NA> 20040206 CN NA <NA> <NA> NA 0
#> 31: <NA> 20040204 OT NA <NA> <NA> NA 0
#> 32: <NA> 20040128 <NA> NA <NA> <NA> NA 0
#> 33: <NA> 20031208 MD NA <NA> <NA> NA 0
#> age_in_years country_code sex
#> <num> <char> <char>
#> 1: 68 <NA> Female
#> 2: 58 <NA> Female
#> 3: 53 <NA> Female
#> 4: NA <NA> Female
#> 5: 48 <NA> Female
#> 6: NA <NA> Male
#> 7: 13 <NA> Female
#> 8: 120 <NA> Female
#> 9: 57 <NA> Male
#> 10: 90 <NA> Male
#> 11: NA <NA> <NA>
#> 12: 71 <NA> Male
#> 13: 71 <NA> Female
#> 14: 79 <NA> Female
#> 15: NA <NA> Female
#> 16: NA <NA> Female
#> 17: 61 <NA> Male
#> 18: 31 <NA> Female
#> 19: 65 <NA> Female
#> 20: 17 <NA> Female
#> 21: NA <NA> Female
#> 22: NA <NA> Female
#> 23: 85 <NA> Female
#> 24: 55 <NA> Male
#> 25: 73 <NA> Male
#> 26: NA <NA> Female
#> 27: 72 <NA> Female
#> 28: NA <NA> Male
#> 29: 53 <NA> Male
#> 30: 17 <NA> Female
#> 31: 38 <NA> Female
#> 32: NA <NA> Female
#> 33: 79 <NA> Female
#> [ reached 'max' / getOption("max.print") -- omitted 68 rows ]
data$demo
#> year quarter primaryid caseid i_f_code foll_seq image event_dt
#> <int> <char> <char> <char> <char> <int> <char> <int>
#> 1: 2004 q1 4263764 4060920 I NA 4263764-6 20020101
#> 2: 2004 q1 4263927 4064250 I NA 4263927-X NA
#> 3: 2004 q1 4264001 4062524 I NA 4264001-9 20031218
#> 4: 2004 q1 4264319 4064506 I NA 4264319-X 20031216
#> 5: 2004 q1 4266745 4056689 I NA 4266745-1 20030529
#> 6: 2004 q1 4268568 4059382 I NA 4268568-6 NA
#> 7: 2004 q1 4268586 3994383 F NA 4268586-8 20030826
#> 8: 2004 q1 4269553 4061181 I NA 4269553-0 20040105
#> 9: 2004 q1 4269590 4062932 I NA 4269590-6 20030602
#> 10: 2004 q1 4269894 4068631 I NA 4269894-7 20030805
#> 11: 2004 q1 4270064 4062312 I NA 4270064-7 NA
#> 12: 2004 q1 4271501 4007339 F 1 4271501-4 20020729
#> 13: 2004 q1 4272687 4072288 I NA 4272687-8 20031220
#> 14: 2004 q1 4274829 4073121 I NA 4274829-7 NA
#> 15: 2004 q1 4276604 4019165 F 2 4276604-6 NA
#> 16: 2004 q1 4276994 4062516 F 2 4276994-4 20031101
#> 17: 2004 q1 4277521 4027660 F 1 4277521-8 NA
#> 18: 2004 q1 4279336 4022360 F 1 4279336-3 20030911
#> 19: 2004 q1 4280316 4049927 F 1 4280316-2 20030617
#> 20: 2004 q1 4280654 4081346 I NA 4280654-3 20040112
#> 21: 2004 q1 4281199 4093363 I NA 4281199-7 NA
#> 22: 2004 q1 4281267 4074460 I NA 4281267-X 20031111
#> 23: 2004 q1 4283791 4091687 I NA 4283791-2 NA
#> 24: 2004 q1 4283960 4008465 F NA 4283960-1 20010717
#> 25: 2004 q1 4284513 4084187 I NA 4284513-1 20030101
#> 26: 2004 q1 4284876 4086360 I NA 4284876-7 NA
#> 27: 2004 q1 4285379 4078728 F 1 4285379-6 20030813
#> 28: 2004 q1 4286029 4087281 I NA 4286029-5 NA
#> 29: 2004 q1 4286712 4072824 F 1 4286712-1 20031209
#> 30: 2004 q1 4286757 4081521 F NA 4286757-1 20031214
#> 31: 2004 q1 4286940 4088359 I NA 4286940-5 20030121
#> 32: 2004 q1 4287019 4088362 I NA 4287019-9 20040121
#> 33: 2004 q1 4289563 4091829 I NA 4289563-7 20030901
#> mfr_dt fda_dt rept_cod mfr_num
#> <int> <int> <char> <char>
#> 1: 20031219 20040102 EXP USA031255171
#> 2: 20031209 20040102 EXP B0317710A
#> 3: 20031219 20040102 EXP JP-JNJFOC-20031204393
#> 4: 20031218 20040105 EXP MEDI-0001221
#> 5: 20040105 20040108 EXP FR-GLAXOSMITHKLINE-B0318977A
#> 6: 20040107 20040112 EXP PHBS2004JP00548
#> 7: 20030904 20040112 EXP US-GLAXOSMITHKLINE-A0424697A
#> 8: 20040106 20040113 EXP US-BRISTOL-MYERS SQUIBB COMPANY-12471421
#> 9: NA 20040112 DIR <NA>
#> 10: NA 20040112 DIR <NA>
#> 11: 20030204 20040114 PER US-GLAXOSMITHKLINE-A0395406A
#> 12: 20040106 20040113 EXP TPA2003A01222
#> 13: 20040109 20040115 EXP 04-01-0044
#> 14: 20031231 20040115 EXP USA040155657
#> 15: 20040108 20040120 EXP US-SHR-03-015202
#> 16: 20040105 20040120 EXP 03P-062-0245595-00
#> 17: 20040105 20040121 EXP DSA_23477_2003
#> 18: 20040112 20040122 EXP FR-JNJFOC-20030905591
#> 19: 20040115 20040126 EXP UK059122
#> 20: 20040119 20040123 EXP 200410213GDS
#> 21: 20030911 20040108 PER HQWYE745017SEP03
#> 22: 20031201 20040123 PER DL2003219
#> 23: 20030415 20040115 PER NSADSS2003017923
#> 24: 20031002 20040202 EXP WAES 0310USA00338
#> 25: NA 20040130 DIR <NA>
#> 26: 20040119 20040202 EXP A001-002-005955
#> 27: 20040121 20040202 EXP 2004194398JP
#> 28: 20040122 20040203 EXP 2004004976
#> 29: 20040126 20040204 EXP 2004193432JP
#> 30: 20040127 20040206 EXP IT-GLAXOSMITHKLINE-B0321668A
#> 31: 20040129 20040205 EXP USA-2004-0012715
#> 32: 20040121 20040205 EXP US_0401100140
#> 33: 20031020 20040126 PER USA030948470
#> mfr_sndr age age_cod gender e_sub wt
#> <char> <num> <char> <char> <char> <num>
#> 1: ELI LILLY AND COMPANY 68 YR F N 82.0
#> 2: GLAXOSMITHKLINE GLOBAL CLINICAL SAFETY 58 YR F N NA
#> 3: CENTOCOR, INC. 53 YR F N 36.8
#> 4: MEDIMUNE, INC. NA <NA> F N NA
#> 5: GLAXOSMITHKLINE 48 YR F Y NA
#> 6: NOVARTIS PHARMACEUTICALS CORP. NA <NA> M Y NA
#> 7: GLAXOSMITHKLINE 13 YR F Y NA
#> 8: BRISTOL-MYERS SQUIBB COMPANY 10 DEC F Y NA
#> 9: <NA> 57 YR M N NA
#> 10: <NA> 90 YR M N NA
#> 11: GLAXOSMITHKLINE NA <NA> <NA> Y NA
#> 12: TAKEDA PHARMACEUTICALS NORTH AMERICA. 71 YR M N 160.0
#> 13: IVAX PHARMACEUTICALS, INC. 71 YR F N NA
#> 14: ELI LILLY AND COMPANY 79 YR F N NA
#> 15: BERLEX LABORATORIES NA <NA> F N 79.4
#> 16: PPD PHARMACOVIGILANCE NA <NA> F N NA
#> 17: BIOVAIL PHARMACEUTICALS INC. 61 YR M N 204.0
#> 18: CENTOCOR, INC. 31 YR F N NA
#> 19: AMGEN 65 YR F N 63.0
#> 20: BAYER PHARMACEUTICALS CORPORATION 17 YR F N NA
#> 21: WYETH LABS (RA) NA <NA> F N NA
#> 22: DANCO LABORATORIES, LLC NA <NA> F N NA
#> 23: JOHNSON + JOHNSON PHARMACEUTICAL 85 YR F N NA
#> 24: MERCK HUMAN HEALTH DIVISION 55 YR M Y NA
#> 25: <NA> 73 YR M N NA
#> 26: EISAI INC. NA <NA> F N NA
#> 27: PFIZER INC. 72 YR F N 52.0
#> 28: WWS PFIZER PHARMACEUTICALS NA <NA> M N NA
#> 29: PFIZER INC. 53 YR M N NA
#> 30: GLAXOSMITHKLINE 17 YR F Y NA
#> 31: PURDUE PHARMA L.P. 38 YR F N NA
#> 32: ELI LILLY AND COMPANY NA <NA> F N NA
#> 33: ELI LILLY AND COMPANY 79 YR F N NA
#> wt_cod rept_dt occp_cod death_dt to_mfr confid v23 caseversion
#> <char> <int> <char> <lgcl> <char> <char> <lgcl> <int>
#> 1: KG 20031223 <NA> NA <NA> <NA> NA 0
#> 2: <NA> 20031219 <NA> NA <NA> <NA> NA 0
#> 3: KG 20031231 MD NA <NA> <NA> NA 0
#> 4: <NA> 20031231 MD NA <NA> <NA> NA 0
#> 5: <NA> 20040108 CN NA <NA> <NA> NA 0
#> 6: <NA> 20040109 MD NA <NA> <NA> NA 0
#> 7: <NA> 20040112 CN NA <NA> <NA> NA 0
#> 8: <NA> 20040113 OT NA <NA> <NA> NA 0
#> 9: <NA> NA PH NA N Y NA 0
#> 10: <NA> NA <NA> NA N Y NA 0
#> 11: <NA> 20040114 CN NA <NA> <NA> NA 0
#> 12: LBS 20040112 MD NA <NA> <NA> NA 0
#> 13: <NA> 20040109 OT NA <NA> <NA> NA 0
#> 14: <NA> 20040107 <NA> NA <NA> <NA> NA 0
#> 15: KG 20040116 CN NA <NA> <NA> NA 0
#> 16: <NA> 20040105 MD NA <NA> <NA> NA 0
#> 17: LBS 20040120 MD NA <NA> <NA> NA 0
#> 18: <NA> 20040121 MD NA <NA> <NA> NA 0
#> 19: KG 20040123 <NA> NA <NA> <NA> NA 0
#> 20: <NA> 20040122 MD NA <NA> <NA> NA 0
#> 21: <NA> 20031223 <NA> NA <NA> <NA> NA 0
#> 22: <NA> 20031229 OT NA <NA> <NA> NA 0
#> 23: <NA> 20040108 OT NA <NA> <NA> NA 0
#> 24: <NA> 20040203 MD NA <NA> <NA> NA 0
#> 25: <NA> 20030124 OT NA Y N NA 0
#> 26: <NA> 20040123 MD NA <NA> <NA> NA 0
#> 27: KG 20040130 MD NA <NA> <NA> NA 0
#> 28: <NA> 20040202 CN NA <NA> <NA> NA 0
#> 29: <NA> 20040202 OT NA <NA> <NA> NA 0
#> 30: <NA> 20040206 CN NA <NA> <NA> NA 0
#> 31: <NA> 20040204 OT NA <NA> <NA> NA 0
#> 32: <NA> 20040128 <NA> NA <NA> <NA> NA 0
#> 33: <NA> 20031208 MD NA <NA> <NA> NA 0
#> age_in_years country_code sex
#> <num> <char> <char>
#> 1: 68 <NA> Female
#> 2: 58 <NA> Female
#> 3: 53 <NA> Female
#> 4: NA <NA> Female
#> 5: 48 <NA> Female
#> 6: NA <NA> Male
#> 7: 13 <NA> Female
#> 8: 120 <NA> Female
#> 9: 57 <NA> Male
#> 10: 90 <NA> Male
#> 11: NA <NA> <NA>
#> 12: 71 <NA> Male
#> 13: 71 <NA> Female
#> 14: 79 <NA> Female
#> 15: NA <NA> Female
#> 16: NA <NA> Female
#> 17: 61 <NA> Male
#> 18: 31 <NA> Female
#> 19: 65 <NA> Female
#> 20: 17 <NA> Female
#> 21: NA <NA> Female
#> 22: NA <NA> Female
#> 23: 85 <NA> Female
#> 24: 55 <NA> Male
#> 25: 73 <NA> Male
#> 26: NA <NA> Female
#> 27: 72 <NA> Female
#> 28: NA <NA> Male
#> 29: 53 <NA> Male
#> 30: 17 <NA> Female
#> 31: 38 <NA> Female
#> 32: NA <NA> Female
#> 33: 79 <NA> Female
#> [ reached 'max' / getOption("max.print") -- omitted 68 rows ]
faers_mget(data, c("indi", "drug"))
#> $indi
#> year quarter primaryid indi_drug_seq
#> <int> <char> <char> <int>
#> 1: 2004 q1 4263927 1004493661
#> 2: 2004 q1 4264001 1004493811
#> 3: 2004 q1 4264001 1004520441
#> 4: 2004 q1 4264001 1004520538
#> 5: 2004 q1 4264319 1004494389
#> ---
#> 153: 2004 q1 4338901 1004786888
#> 154: 2004 q1 4346899 1004815291
#> 155: 2004 q1 4346899 1004815291
#> 156: 2004 q1 4347265 1004816501
#> 157: 2004 q1 4373559 1004923573
#> indi_pt
#> <char>
#> 1: DIABETES MELLITUS NON-INSULIN-DEPENDENT
#> 2: RHEUMATOID ARTHRITIS
#> 3: RHEUMATOID ARTHRITIS
#> 4: RHEUMATOID ARTHRITIS
#> 5: ANTIVIRAL PROPHYLAXIS
#> ---
#> 153: RHEUMATOID ARTHRITIS
#> 154: ATTENTION DEFICIT/HYPERACTIVITY DISORDER
#> 155: PERVASIVE DEVELOPMENTAL DISORDER
#> 156: FRACTURED SACRUM
#> 157: LIPIDS INCREASED
#>
#> $drug
#> year quarter primaryid drug_seq role_cod drugname val_vbm route
#> <int> <char> <char> <int> <char> <char> <int> <char>
#> 1: 2004 q1 4263764 1004492874 PS HUMALOG 1 <NA>
#> 2: 2004 q1 4263764 1004515789 SS HUMULIN L 1 <NA>
#> 3: 2004 q1 4263764 1004515793 SS HUMULIN R 1 <NA>
#> 4: 2004 q1 4263927 1004493661 PS AVANDIA 1 ORAL
#> 5: 2004 q1 4263927 1004529123 C GLYBURIDE 1 <NA>
#> ---
#> 337: 2004 q1 4373559 1004924622 C ZETIA 1 <NA>
#> 338: 2004 q1 4373586 1004923625 PS CRESTOR 1 ORAL
#> 339: 2004 q1 4373706 1004923791 PS CRESTOR 1 <NA>
#> 340: 2004 q1 4373706 1004925107 SS NIACIN 1 <NA>
#> 341: 2004 q1 4373706 1004925121 C LIPITOR 1 <NA>
#> dose_vbm dechal rechal lot_num exp_dt nda_num v13
#> <char> <char> <char> <char> <int> <char> <lgcl>
#> 1: <NA> D <NA> <NA> NA 20563 NA
#> 2: 15 U/2 DAY D <NA> <NA> NA <NA> NA
#> 3: <NA> N <NA> <NA> NA <NA> NA
#> 4: ORAL Y D <NA> NA 21071 NA
#> 5: <NA> <NA> <NA> <NA> NA <NA> NA
#> ---
#> 337: <NA> <NA> <NA> <NA> NA <NA> NA
#> 338: 10 MG PO D D <NA> NA 21366 NA
#> 339: <NA> D D <NA> NA 21366 NA
#> 340: <NA> D D <NA> NA <NA> NA
#> 341: <NA> <NA> <NA> <NA> NA <NA> NA
#>
faers_mget(data, c("indi", "demo"))
#> $indi
#> year quarter primaryid indi_drug_seq
#> <int> <char> <char> <int>
#> 1: 2004 q1 4263927 1004493661
#> 2: 2004 q1 4264001 1004493811
#> 3: 2004 q1 4264001 1004520441
#> 4: 2004 q1 4264001 1004520538
#> 5: 2004 q1 4264319 1004494389
#> ---
#> 153: 2004 q1 4338901 1004786888
#> 154: 2004 q1 4346899 1004815291
#> 155: 2004 q1 4346899 1004815291
#> 156: 2004 q1 4347265 1004816501
#> 157: 2004 q1 4373559 1004923573
#> indi_pt
#> <char>
#> 1: DIABETES MELLITUS NON-INSULIN-DEPENDENT
#> 2: RHEUMATOID ARTHRITIS
#> 3: RHEUMATOID ARTHRITIS
#> 4: RHEUMATOID ARTHRITIS
#> 5: ANTIVIRAL PROPHYLAXIS
#> ---
#> 153: RHEUMATOID ARTHRITIS
#> 154: ATTENTION DEFICIT/HYPERACTIVITY DISORDER
#> 155: PERVASIVE DEVELOPMENTAL DISORDER
#> 156: FRACTURED SACRUM
#> 157: LIPIDS INCREASED
#>
#> $demo
#> year quarter primaryid caseid i_f_code foll_seq image event_dt
#> <int> <char> <char> <char> <char> <int> <char> <int>
#> 1: 2004 q1 4263764 4060920 I NA 4263764-6 20020101
#> 2: 2004 q1 4263927 4064250 I NA 4263927-X NA
#> 3: 2004 q1 4264001 4062524 I NA 4264001-9 20031218
#> 4: 2004 q1 4264319 4064506 I NA 4264319-X 20031216
#> 5: 2004 q1 4266745 4056689 I NA 4266745-1 20030529
#> 6: 2004 q1 4268568 4059382 I NA 4268568-6 NA
#> 7: 2004 q1 4268586 3994383 F NA 4268586-8 20030826
#> 8: 2004 q1 4269553 4061181 I NA 4269553-0 20040105
#> 9: 2004 q1 4269590 4062932 I NA 4269590-6 20030602
#> 10: 2004 q1 4269894 4068631 I NA 4269894-7 20030805
#> 11: 2004 q1 4270064 4062312 I NA 4270064-7 NA
#> 12: 2004 q1 4271501 4007339 F 1 4271501-4 20020729
#> 13: 2004 q1 4272687 4072288 I NA 4272687-8 20031220
#> 14: 2004 q1 4274829 4073121 I NA 4274829-7 NA
#> 15: 2004 q1 4276604 4019165 F 2 4276604-6 NA
#> 16: 2004 q1 4276994 4062516 F 2 4276994-4 20031101
#> 17: 2004 q1 4277521 4027660 F 1 4277521-8 NA
#> 18: 2004 q1 4279336 4022360 F 1 4279336-3 20030911
#> 19: 2004 q1 4280316 4049927 F 1 4280316-2 20030617
#> 20: 2004 q1 4280654 4081346 I NA 4280654-3 20040112
#> 21: 2004 q1 4281199 4093363 I NA 4281199-7 NA
#> 22: 2004 q1 4281267 4074460 I NA 4281267-X 20031111
#> 23: 2004 q1 4283791 4091687 I NA 4283791-2 NA
#> 24: 2004 q1 4283960 4008465 F NA 4283960-1 20010717
#> 25: 2004 q1 4284513 4084187 I NA 4284513-1 20030101
#> 26: 2004 q1 4284876 4086360 I NA 4284876-7 NA
#> 27: 2004 q1 4285379 4078728 F 1 4285379-6 20030813
#> 28: 2004 q1 4286029 4087281 I NA 4286029-5 NA
#> 29: 2004 q1 4286712 4072824 F 1 4286712-1 20031209
#> 30: 2004 q1 4286757 4081521 F NA 4286757-1 20031214
#> 31: 2004 q1 4286940 4088359 I NA 4286940-5 20030121
#> 32: 2004 q1 4287019 4088362 I NA 4287019-9 20040121
#> 33: 2004 q1 4289563 4091829 I NA 4289563-7 20030901
#> mfr_dt fda_dt rept_cod mfr_num
#> <int> <int> <char> <char>
#> 1: 20031219 20040102 EXP USA031255171
#> 2: 20031209 20040102 EXP B0317710A
#> 3: 20031219 20040102 EXP JP-JNJFOC-20031204393
#> 4: 20031218 20040105 EXP MEDI-0001221
#> 5: 20040105 20040108 EXP FR-GLAXOSMITHKLINE-B0318977A
#> 6: 20040107 20040112 EXP PHBS2004JP00548
#> 7: 20030904 20040112 EXP US-GLAXOSMITHKLINE-A0424697A
#> 8: 20040106 20040113 EXP US-BRISTOL-MYERS SQUIBB COMPANY-12471421
#> 9: NA 20040112 DIR <NA>
#> 10: NA 20040112 DIR <NA>
#> 11: 20030204 20040114 PER US-GLAXOSMITHKLINE-A0395406A
#> 12: 20040106 20040113 EXP TPA2003A01222
#> 13: 20040109 20040115 EXP 04-01-0044
#> 14: 20031231 20040115 EXP USA040155657
#> 15: 20040108 20040120 EXP US-SHR-03-015202
#> 16: 20040105 20040120 EXP 03P-062-0245595-00
#> 17: 20040105 20040121 EXP DSA_23477_2003
#> 18: 20040112 20040122 EXP FR-JNJFOC-20030905591
#> 19: 20040115 20040126 EXP UK059122
#> 20: 20040119 20040123 EXP 200410213GDS
#> 21: 20030911 20040108 PER HQWYE745017SEP03
#> 22: 20031201 20040123 PER DL2003219
#> 23: 20030415 20040115 PER NSADSS2003017923
#> 24: 20031002 20040202 EXP WAES 0310USA00338
#> 25: NA 20040130 DIR <NA>
#> 26: 20040119 20040202 EXP A001-002-005955
#> 27: 20040121 20040202 EXP 2004194398JP
#> 28: 20040122 20040203 EXP 2004004976
#> 29: 20040126 20040204 EXP 2004193432JP
#> 30: 20040127 20040206 EXP IT-GLAXOSMITHKLINE-B0321668A
#> 31: 20040129 20040205 EXP USA-2004-0012715
#> 32: 20040121 20040205 EXP US_0401100140
#> 33: 20031020 20040126 PER USA030948470
#> mfr_sndr age age_cod gender e_sub wt
#> <char> <num> <char> <char> <char> <num>
#> 1: ELI LILLY AND COMPANY 68 YR F N 82.0
#> 2: GLAXOSMITHKLINE GLOBAL CLINICAL SAFETY 58 YR F N NA
#> 3: CENTOCOR, INC. 53 YR F N 36.8
#> 4: MEDIMUNE, INC. NA <NA> F N NA
#> 5: GLAXOSMITHKLINE 48 YR F Y NA
#> 6: NOVARTIS PHARMACEUTICALS CORP. NA <NA> M Y NA
#> 7: GLAXOSMITHKLINE 13 YR F Y NA
#> 8: BRISTOL-MYERS SQUIBB COMPANY 10 DEC F Y NA
#> 9: <NA> 57 YR M N NA
#> 10: <NA> 90 YR M N NA
#> 11: GLAXOSMITHKLINE NA <NA> <NA> Y NA
#> 12: TAKEDA PHARMACEUTICALS NORTH AMERICA. 71 YR M N 160.0
#> 13: IVAX PHARMACEUTICALS, INC. 71 YR F N NA
#> 14: ELI LILLY AND COMPANY 79 YR F N NA
#> 15: BERLEX LABORATORIES NA <NA> F N 79.4
#> 16: PPD PHARMACOVIGILANCE NA <NA> F N NA
#> 17: BIOVAIL PHARMACEUTICALS INC. 61 YR M N 204.0
#> 18: CENTOCOR, INC. 31 YR F N NA
#> 19: AMGEN 65 YR F N 63.0
#> 20: BAYER PHARMACEUTICALS CORPORATION 17 YR F N NA
#> 21: WYETH LABS (RA) NA <NA> F N NA
#> 22: DANCO LABORATORIES, LLC NA <NA> F N NA
#> 23: JOHNSON + JOHNSON PHARMACEUTICAL 85 YR F N NA
#> 24: MERCK HUMAN HEALTH DIVISION 55 YR M Y NA
#> 25: <NA> 73 YR M N NA
#> 26: EISAI INC. NA <NA> F N NA
#> 27: PFIZER INC. 72 YR F N 52.0
#> 28: WWS PFIZER PHARMACEUTICALS NA <NA> M N NA
#> 29: PFIZER INC. 53 YR M N NA
#> 30: GLAXOSMITHKLINE 17 YR F Y NA
#> 31: PURDUE PHARMA L.P. 38 YR F N NA
#> 32: ELI LILLY AND COMPANY NA <NA> F N NA
#> 33: ELI LILLY AND COMPANY 79 YR F N NA
#> wt_cod rept_dt occp_cod death_dt to_mfr confid v23 caseversion
#> <char> <int> <char> <lgcl> <char> <char> <lgcl> <int>
#> 1: KG 20031223 <NA> NA <NA> <NA> NA 0
#> 2: <NA> 20031219 <NA> NA <NA> <NA> NA 0
#> 3: KG 20031231 MD NA <NA> <NA> NA 0
#> 4: <NA> 20031231 MD NA <NA> <NA> NA 0
#> 5: <NA> 20040108 CN NA <NA> <NA> NA 0
#> 6: <NA> 20040109 MD NA <NA> <NA> NA 0
#> 7: <NA> 20040112 CN NA <NA> <NA> NA 0
#> 8: <NA> 20040113 OT NA <NA> <NA> NA 0
#> 9: <NA> NA PH NA N Y NA 0
#> 10: <NA> NA <NA> NA N Y NA 0
#> 11: <NA> 20040114 CN NA <NA> <NA> NA 0
#> 12: LBS 20040112 MD NA <NA> <NA> NA 0
#> 13: <NA> 20040109 OT NA <NA> <NA> NA 0
#> 14: <NA> 20040107 <NA> NA <NA> <NA> NA 0
#> 15: KG 20040116 CN NA <NA> <NA> NA 0
#> 16: <NA> 20040105 MD NA <NA> <NA> NA 0
#> 17: LBS 20040120 MD NA <NA> <NA> NA 0
#> 18: <NA> 20040121 MD NA <NA> <NA> NA 0
#> 19: KG 20040123 <NA> NA <NA> <NA> NA 0
#> 20: <NA> 20040122 MD NA <NA> <NA> NA 0
#> 21: <NA> 20031223 <NA> NA <NA> <NA> NA 0
#> 22: <NA> 20031229 OT NA <NA> <NA> NA 0
#> 23: <NA> 20040108 OT NA <NA> <NA> NA 0
#> 24: <NA> 20040203 MD NA <NA> <NA> NA 0
#> 25: <NA> 20030124 OT NA Y N NA 0
#> 26: <NA> 20040123 MD NA <NA> <NA> NA 0
#> 27: KG 20040130 MD NA <NA> <NA> NA 0
#> 28: <NA> 20040202 CN NA <NA> <NA> NA 0
#> 29: <NA> 20040202 OT NA <NA> <NA> NA 0
#> 30: <NA> 20040206 CN NA <NA> <NA> NA 0
#> 31: <NA> 20040204 OT NA <NA> <NA> NA 0
#> 32: <NA> 20040128 <NA> NA <NA> <NA> NA 0
#> 33: <NA> 20031208 MD NA <NA> <NA> NA 0
#> age_in_years country_code sex
#> <num> <char> <char>
#> 1: 68 <NA> Female
#> 2: 58 <NA> Female
#> 3: 53 <NA> Female
#> 4: NA <NA> Female
#> 5: 48 <NA> Female
#> 6: NA <NA> Male
#> 7: 13 <NA> Female
#> 8: 120 <NA> Female
#> 9: 57 <NA> Male
#> 10: 90 <NA> Male
#> 11: NA <NA> <NA>
#> 12: 71 <NA> Male
#> 13: 71 <NA> Female
#> 14: 79 <NA> Female
#> 15: NA <NA> Female
#> 16: NA <NA> Female
#> 17: 61 <NA> Male
#> 18: 31 <NA> Female
#> 19: 65 <NA> Female
#> 20: 17 <NA> Female
#> 21: NA <NA> Female
#> 22: NA <NA> Female
#> 23: 85 <NA> Female
#> 24: 55 <NA> Male
#> 25: 73 <NA> Male
#> 26: NA <NA> Female
#> 27: 72 <NA> Female
#> 28: NA <NA> Male
#> 29: 53 <NA> Male
#> 30: 17 <NA> Female
#> 31: 38 <NA> Female
#> 32: NA <NA> Female
#> 33: 79 <NA> Female
#> [ reached 'max' / getOption("max.print") -- omitted 68 rows ]
#>
faers_primaryid(data)
#> [1] "4263764" "4263927" "4264001" "4264319" "4266745" "4268568" "4268586"
#> [8] "4269553" "4269590" "4269894" "4270064" "4271501" "4272687" "4274829"
#> [15] "4276604" "4276994" "4277521" "4279336" "4280316" "4280654" "4281199"
#> [22] "4281267" "4283791" "4283960" "4284513" "4284876" "4285379" "4286029"
#> [29] "4286712" "4286757" "4286940" "4287019" "4289563" "4290441" "4290950"
#> [36] "4291212" "4291571" "4291654" "4292881" "4293613" "4293737" "4294153"
#> [43] "4294372" "4294513" "4295353" "4297303" "4297385" "4298644" "4299109"
#> [50] "4300112" "4300793" "4301549" "4303198" "4303368" "4304042" "4304072"
#> [57] "4304923" "4305272" "4306018" "4307962" "4309138" "4309390" "4309892"
#> [64] "4310442" "4310686" "4310779" "4310862" "4312635" "4314135" "4314728"
#> [71] "4316846" "4316948" "4317126" "4317723" "4318270" "4318479" "4318770"
#> [78] "4319252" "4322216" "4322271" "4322418" "4322977" "4324022" "4324041"
#> [85] "4324746" "4325623" "4326344" "4327943" "4328323" "4330031" "4330060"
#> [92] "4331457" "4334007" "4338901" "4346258" "4346899" "4347265" "4373559"
#> [99] "4373586" "4373706"
faers_keep(data, primaryid = sample(faers_primaryid(data), 20L))
#> FAERS data from 1 Quarterly ascii file
#> Total reports: 20 (with duplicates)
faers_filter(data, .fn = function(x) {
sample(x$primaryid, 100L)
}, .field = "demo")
#> FAERS data from 1 Quarterly ascii file
#> Total reports: 100 (with duplicates)